Therapy response in brain tumor cells linked to disease prognosis

December 13, 2016

The brain tumour form glioblastoma is difficult to treat and has very poor prognosis. In a new study, published today in the journal Cell Reports, scientists from Uppsala University show that a type of stem cell in the tumour is present in different states, with different response to drugs and radiation. The results may open an avenue towards development of new treatment strategies designed to reverse therapy resistant cell states to more sensitive states.

Glioblastoma is a very aggressive tumour form and affected patients only survive for, on average, approximately a year after diagnosis. Researchers believe that the difficulties in treating the disease is caused by cells in the tumours called glioma-initiating cells (GICs), a kind of stem cells that can start growing again, after treatment has been finished.

The new results from Uppsala University show that a single tumour contained GICs in different states that are differently resistant to therapy. Cell states that were resistant to radiation were also resistant to drugs, and states that were resistant to one drugs tended to be resistant to most of the other tested drugs.

"Another interesting result was that the GICs did not fall into distinct response groups. Instead the difference in their response can best be described as a continuum of cells with different resistance levels. We also discovered a relationship between the resistance level and molecular characteristics of the tumour that are associated with disease prognosis. A resistant cell state of the GICs was linked to characteristics associated with and a sensitive cell state was linked to characteristics associated with better outcome", says Anna Segerman, who has led the study together with Bengt Westermark, Department of Immunology, Genetics and Pathology.

A new strategy to treat glioblastoma could be to target the intertumour heterogeneity, i.e. the presence in the same tumour of a mix of GICs that have different resistance levels and are linked to different prognoses.

"We hypothesize that the mix of GICs with different resistance levels is formed by a drift between the different cell states. With more knowledge about the mechanisms behind this it might be possible to develop new therapies that reprogram the GICs to render them more sensitive to radiation and drugs", says Bengt Westermark.

Explore further: The cell of origin in childhood brain tumors affects susceptibility to therapy

More information: Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition, Cell Reports, DOI: 10.1016/j.celrep.2016.11.056

Related Stories

Forensic DNA analysis checks the origin of cultured cells

August 31, 2016

Cell lines are cultured cells that are commonly used in medical research. New results from Uppsala University show that such cells are not always what they are assumed to be. Using genetic analyses, the researchers showed ...

Harnessing the ID in glioma

December 17, 2012

Gliomas are the most common form of brain tumor. They are highly aggressive and effective treatments are not currently available. The tumors contain glioma initiating cells (GICs), a population that is highly similar to neural ...

Artificial intelligence reveals mechanism behind brain tumour

September 19, 2016

Researchers at Uppsala University have used computer modelling to study how brain tumours arise. The study, which is published today in the journal EBioMedicine, illustrated how researchers in the future will be able to use ...

Scientists aim to slow fast growth of cancer cells

October 4, 2016

The fight against cancer is a marathon, fought step by step, inch by inch. While breakthroughs may be rare, a new study from the Faculty of Medicine & Dentistry is giving greater insight into the growth of cancer cells and ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.